Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
The rail car maker is likely riding into a slower period of demand for its products, which investors should keep in mind when considering it as a dividend play.
Financials and energy ETFs aren't faring well in the current environment, but there still is a way to make money on them.
It's hard to put much stock in achieving real progress on trade talks with China, and with the yield curve inverting and global economies sagging it's time to be on guard in the markets.
The two commodities are in downtrends, which when combined with an economic expansion that is long in the tooth could indicate a recession is on the horizon.
Haverty Furniture Cos., aka Havertys, has paid a cash dividend every year for more than eight decades and occasionally surprises shareholders with a special payout.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
It will take time to determine the impact of new tariffs on consumer prices, business bottom lines and the achievement of a trade deal with China.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.